Unity Clinical Research
Welcome,         Profile    Billing    Logout  
 6 Trials 
14 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Fishman, Marc J
CBOT-OUD, NCT04850664: Computerized Chemosensory-Based Orbitofrontal Cortex (CBOT) for Opioid Use Disorder

Recruiting
2
190
US
CBOT + TAU, plant based essential oils, Sham + TAU
Evon Medics LLC, National Institute on Drug Abuse (NIDA), Howard University, Family and Medical Counseling Service, Inc, Maryland Treatment Centers @ ARTC, Clinics of Dr. Edwin Chapman, MD, PC @ MHDG
Opioid Use Disorder, Moderate, Opioid Use Disorder, Severe, Withdrawal Symptoms, Craving, Negative Affectivity
11/22
12/22
EDITOR, NCT06434818: Enhanced Digital-Chemosensory-Based Olfactory Training for Remote Management of Substance Use Disorders

Recruiting
2
300
US
EDITOR (CBOT with olfactory stimulants, OFC tasks & remote monitoring of treatment compliance), EDITOR plus Treatment-As-Usual (TAU), CBOT with olfactory stimulants & OFC tasks, CBOT active plus TAU, CBOT Sham, CBOT passive plus TAU
Evon Medics LLC, Howard University, Maryland Treatment Center, Clinics of Dr. Edwin Chapman, MD, PC @ MHDG, National Institute on Drug Abuse (NIDA)
Substance Use Disorders, Opioid Use Disorder, Alcohol Use Disorder, Cocaine Use Disorder, Methamphetamine-dependence
03/25
06/25
NCT06384157: Proof of Concept and Dose-ranging Study of INDV-2000 in Individuals With Moderate to Severe Opioid Use Disorder

Recruiting
2
300
US
INDV-2000, Placebo
Indivior Inc.
Opioid Use Disorder
08/25
09/25
NCT04464980: Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD)

Recruiting
2
2190
US
SL-BUP, sublingual buprenorphine, Suboxone, XR-BUP, extended-release buprenorphine, CAM2038, Brixadi, XR-NTX, extended-release naltrexone, Vivitrol, MM, MMR, MMD
NYU Langone Health, New York State Psychiatric Institute, Columbia University, Harvard Medical School (HMS and HSDM), Mclean Hospital, National Institute on Drug Abuse (NIDA), The Emmes Company, LLC
Opioid Use Disorder (OUD)
07/26
12/26
NCT05860959: SUBLOCADE Long-term Outcomes

Recruiting
N/A
1200
Europe, Canada, US, RoW
Indivior Inc.
Opioid Use Disorder
08/27
08/27
Rawaf, Mustafa
NCT06419608: Efficacy and Safety Study of BHV-7000 Monotherapy in Major Depression

Recruiting
2
300
US
BHV-7000, Placebo
Biohaven Therapeutics Ltd.
Major Depressive Disorder
05/25
07/25
ENLIGHTEN, NCT05113771: A Biomarker-Guided, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Liafensine in Patients With Treatment-Resistant Depression

Completed
2
197
Canada, US
Liafensine, Placebo
Denovo Biopharma LLC
Treatment Resistant Depression
02/24
03/24
NCT06384157: Proof of Concept and Dose-ranging Study of INDV-2000 in Individuals With Moderate to Severe Opioid Use Disorder

Recruiting
2
300
US
INDV-2000, Placebo
Indivior Inc.
Opioid Use Disorder
08/25
09/25
Levin, Jarad
NCT06436183: A Study of the Effects of Camoteskimab in Adults With Moderate to Severe Atopic Dermatitis

Recruiting
2
60
Canada, US
Camoteskimab, APL-9109, AVTX-007, CERC-007, AEVI-007, MEDI2338, Placebo
Apollo Therapeutics Ltd
Atopic Dermatitis, Atopic, Dermatitis, Dermatologic Disease, Eczema, Eczema Atopic Dermatitis, Eczema, Atopic
02/25
06/25
Burroughs, Kristi
INDV-6000-401, NCT04995029: Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in High-risk Users

Completed
4
785
Canada, US
Transmucosal Buprenorphine, Extended-release Buprenorphine, RBP-6000, SUBLOCADE
Indivior Inc.
Moderate to Severe Opioid-use Disorder
06/24
06/24
NCT06436183: A Study of the Effects of Camoteskimab in Adults With Moderate to Severe Atopic Dermatitis

Recruiting
2
60
Canada, US
Camoteskimab, APL-9109, AVTX-007, CERC-007, AEVI-007, MEDI2338, Placebo
Apollo Therapeutics Ltd
Atopic Dermatitis, Atopic, Dermatitis, Dermatologic Disease, Eczema, Eczema Atopic Dermatitis, Eczema, Atopic
02/25
06/25
NCT06384157: Proof of Concept and Dose-ranging Study of INDV-2000 in Individuals With Moderate to Severe Opioid Use Disorder

Recruiting
2
300
US
INDV-2000, Placebo
Indivior Inc.
Opioid Use Disorder
08/25
09/25
Catallini, Jeff
NCT06384157: Proof of Concept and Dose-ranging Study of INDV-2000 in Individuals With Moderate to Severe Opioid Use Disorder

Recruiting
2
300
US
INDV-2000, Placebo
Indivior Inc.
Opioid Use Disorder
08/25
09/25
Olaiya, Olubukola
NCT06384157: Proof of Concept and Dose-ranging Study of INDV-2000 in Individuals With Moderate to Severe Opioid Use Disorder

Recruiting
2
300
US
INDV-2000, Placebo
Indivior Inc.
Opioid Use Disorder
08/25
09/25

Download Options